2023-01-25 07:30:00

TOM Medications concludes another round of funding at over CHF 1.3 million

Logo PR Newswire
PR Newswire

The latest round of funding for TOM Medications was hugely oversubscribed, at CHF 1.3 million, or over 120 percent. TOM Medications hopes the new funding will help boost its turnover, expand its community, and tap into new markets.

ZURICH, Jan. 25, 2023 /PRNewswire/ -- TOM Medications has already notched numerous successes since its launch in June 2020. Around 30 million interactions have already taken place via the app, and treatment compliance among TOM app users is 83 percent – much higher than the approximate average of 50 percent usually achieved by those with chronic health conditions. As the recent round of funding showed, investors believe there is plenty more potential in the virtual medicine cabinet: it was massively oversubscribed, at over CHF 1.3 million, or more than 120 percent.

TOM Medications Logo

'Due to tangible success in 2022, the majority of previous investors were immediately willing to reinvest,' says TOM founder and CEO Sven Beichler. These investors include health insurance company Sanitas, which collaborated with TOM on a May 2022 pilot project allowing Sanitas customers to use a program in the TOM app. 'Following the successful implementation of the joint pilot project, we're happy to continue supporting TOM Medications in its development. We're also delighted that Galenica is now on board, too,' says Sanitas CEO Dr. Andreas Schönenberger.

Galenica was impressed by TOM's existing investors, as well as its forward-looking concept. The leading listed, fully integrated healthcare service provider in Switzerland, which operates the pharmacy chains Amavita, Sun Store, and – together with Coop – Coop Vitality, is now also on board. 'We want to support our customers with health services that meet their needs. We believe the TOM app dramatically improves patient compliance and, therefore, the health of people with chronic health conditions. That's why we chose to get on board with TOM,' says Daniele Madonna, Chief Healthcare Officer at Galenica AG.

Boosting turnover, growing the community, and expanding into Germany
The new resources allow TOM Medications to make its plans a reality: 'We want to keep growing – our customer base as well as our turnover, too', adds Sven Beichler. 'We also want to strengthen and expand our community. After all, it's an essential aspect of what we do at TOM.' The TOM app is already available in several countries. The business is set to step up its activity: 'Our next step is to widen access to our services in Germany going forward. Our northern neighbours also offer plenty of potentials to increase treatment compliance and simplify access to pharmacy services in a specific way.'

About Innovation 6 AG – TOM Medications
TOM Medications, a product of Innovation 6 AG, headquartered in Wermatswil (Zurich), was launched in June 2020 and offers solutions for simplifying medication management. CEO: Sven Beichler. Learn more at www.tommedications.com

Contact TOM MEDICATIONS

Sven Beichler

CEO

TOM Medications

sven.beichler@innovation6.ch

Media contact:

Brigitte Kaps

CEO

Rent a PR AG

Tel +41 (0) 79 289 20 42

mail@rentapr.ch

About Sanitas
With around 849,000 customers, Sanitas is one of Switzerland's most significant health insurance companies. It offers tailored health insurance solutions for obligatory basic and supplementary insurance coverage. www.sanitas.ch

About Galenica AG
Galenica is the leading fully integrated health services provider in Switzerland. Galenica operates Switzerland's biggest pharmacy network, with more than 500 of its own pharmacies, run as joint ventures and by independent partners. Galenica also develops and carries its well-known brands and products, in addition to exclusive brands and products from its partners, and offers its customers various in-person healthcare services and checks. Galenica is also the leading provider of pre-wholesale and wholesale distribution services and database services for the Swiss healthcare market. Galenica is listed on the Swiss stock market (SIX Swiss Exchange, GALE, Valoren number 36,067,446). More information is available at www.galenica.com.

Logo - https://mma.prnewswire.com/media/1900812/TOM_Medications_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/tom-medications-concludes-another-round-of-funding-at-over-chf-1-3-million-301729131.html

Logo PR Newswire
TechnologyPress Release2023-01-24 10:45:00
SAN FRANCISCO, Jan. 24, 2023 /PRNewswire/ -- The global E-Prescribing market size is expected to reach USD 19.28 billion by 2030, expanding at a CAGR of...

Logo EIN Presswire
HealthPress Release2023-01-24 09:48:13
Digital Medicines Market Trends Digital medicine technology is an innovative technology that bridged the gap between healthcare and digital technology....

Logo PR Newswire
HealthPress Release2023-01-24 18:30:00
NEW YORK, Jan. 24, 2023 /PRNewswire/ -- The ophthalmology therapeutics market by product, type, and geography - forecast and analysis 2023-2027 report has...

Logo GlobeNewswire
The global genitourinary drugs market size was valued at USD 32 billion in 2021 and is expected to surpass USD 68.51 billion by 2030, registering a CAGR of...

Logo GlobeNewswire
EconomyPress Release2023-01-24 15:30:00
Healthcare Analytics Market Trends and Insights By Type (Predictive, Cognitive), Component (Software, Services), Delivery Model (On-Premise), Application...

Logo PR Newswire
HealthPress Release2023-01-24 18:00:00
CHICAGO, Jan. 24, 2023 /PRNewswire/ -- According to Arizton's latest research report, the therapeutic contact lenses market is to grow at a CAGR of 5% during...

Logo EIN Presswire
HealthPress Release2023-01-24 09:44:19
Report covers all details inside analysis and outlook according to The Insight Partners. NEW YORK, UNITED STATES, January 24, 2023 / EINPresswire.com / --...

Logo GlobeNewswire
EconomyPress Release2023-01-24 14:30:00
Burlingame, Jan. 24, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, Global Cancer Therapy Market is estimated to be valued at US$ 1 84. 8 b...

Logo EIN Presswire
Biosimilar Hormones Global Market Report 2023 – Market Size, Trends, And Market Forecast 2023-2032 The Business Research Companys Biosimilar Hormones Global...

Logo GlobeNewswire
EconomyPress Release2023-01-24 09:34:00
HEOR services industry is anticipated to register 14% CAGR between 2023 and 2032 owing to increasing R&D expenditure worldwide. Selbyville, Delaware,...

Logo GlobeNewswire
SciencePress Release2023-01-24 21:01:00
CAMBRIDGE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers...

Logo GlobeNewswire
HealthPress Release2023-01-24 14:00:00
Long-standing, Employee-driven Support of Philanthropic Efforts Grows 20% Year-Over-Year BOWIE, Md., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Inovalon, a leading...

Logo EIN Presswire
Cardiovascular Needle Market report initially provides a basic overview of the industry that covers applications, definition and companies analysis NEW YORK,...

Logo PR Newswire
HealthPress Release2023-01-24 17:40:00
SILVER SPRING, Md., Jan. 24, 2023 /PRNewswire/ -- Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the...

Logo PR Newswire
HealthPress Release2023-01-24 11:30:00
DUBLIN, Jan. 24, 2023 /PRNewswire/ -- The "China Anti-Rheumatic Drug Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's...

Logo PR Newswire
HealthPress Release2023-01-24 13:00:00
The organ care system market for heart is predicted to experience striking growth by 2026, owing to the increasing incidences of cardiovascular diseases...

Logo PR Newswire
HealthPress Release2023-01-24 10:56:00
Two successful exits – Syndesi and BioPhero Four portfolio companies reported clinical data from first in class targets (Galecto, NMD Pharma, Heparegenix and...

Logo PR Newswire
HealthPress Release2023-01-24 13:07:00
MORRISVILLE, N.C, Jan. 24, 2023 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions that advance a wide variety of...

Logo EIN Presswire
HealthPress Release2023-01-23 13:38:17
Emergen Research Logo Increasing number of drug relapse and drug resistance cases and application of QSP in drug development processes are some key factors...

Logo PR Newswire
HealthPress Release2023-01-24 14:30:00
Atlas medical technologies GmbH strengthens equity by 2.4 million euros in Series A. The German medical technology company uses the capital increase for...